27/05/2016 00:36:19 1-888-992-3836 (toll free) Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

05/23/20164:40PMDJNSamsung Targets U.S. Drug Market With Remicade Knockoff
SEOUL—Samsung Group said Tuesday its near-replica of Johnson & Johnson's blockbuster arthritis drug Remicade has been accepted for review by the U.S. Food and Drug Administration, marking the South Korean conglomerate's first attempt to sell drugs to Americans, alongside its popular smartphones and... More...>>
05/23/201611:15AMBWBristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference on Saturday, June 4, 2016, at 7 p.m. EDT (6 p.m. CDT) to discuss company strategy and review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of company... More...>>
05/19/20167:55AMGLOBEInovalon Announces Agreement with Bristol-Myers Squibb to Focus on Real World Outcomes & Value-Based Contracting Initiatives
BOWIE, Md., May 19, 2016 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company providing advanced, cloud-based analytics and data-driven intervention platforms to the healthcare industry, today announced that it has entered into an agreement with Bristol-Myers Squibb (NYSE:BMY), a global BioPharma company... More...>>
05/18/201610:27PMDJNNew Hope for Melanoma Patients -- Update
By Peter Loftus A new study reinforces the potential of a new class of expensive immune-boosting drugs to prolong the lives of people with a deadly form of skin cancer. An estimated 40% of 655 people who took Merck & Co.'s Keytruda in a clinical trial to treat advanced melanoma were still alive three years after... More...>>
05/18/20165:40PMBWTwo-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Ad...
Opdivo demonstrated an overall survival benefit at the landmark two-year time point versus docetaxel in previously treated advanced non-small cell lung cancer, across histologies Data show benefit with Opdivo in the overall population, with nearly double (CheckMate -057) and triple (Checkmate -017) the patients alive at... More...>>
05/18/20166:59AMBWBreadth & Depth of Bristol-Myers Squibb’s Immuno-Oncology Clinical Development Program to be Showcased at 2016 American Soc...
Long-term survival data for a broad set of tumor types including advanced non-small and small cell lung cancer, advanced melanoma, and up to 5-year follow up in renal cell carcinoma, to be presented Broad data set for the Opdivo and Yervoy combination in several tumors, including first-line non-small cell lung cancer... More...>>
05/17/20167:04PMBWOpdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma...
Approval based on combined data from two trials, CheckMate -205 and -039, in patients with classical Hodgkin lymphoma who have relapsed or progressed after auto-HSCT and post-transplantation brentuximab vedotin Accelerated approval of Opdivo based on overall response rate in classical Hodgkin lymphoma patients who have... More...>>
05/17/20161:00PMBWBristol-Myers Squibb Opens Expanded Biologics Facility
$280 Million Project Increases Workforce, Adds New Capabilities Bristol-Myers Squibb (NYSE:BMY) today celebrated the completion of a major expansion at its Devens, MA biologics facility designed to accelerate development of the company’s growing portfolio of biologics medicines. This Smart News Release features multimedia... More...>>
05/12/20164:01PMGLOBEHTG Molecular Diagnostics Announces Immuno-Oncology Research Collaboration Agreement with Bristol-Myers Squibb
TUCSON, Ariz., May 12, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced a research collaboration agreement with Bristol-Myers Squibb (NYSE:BMY) to evaluate the potential for immuno-oncology molecular profiling... More...>>
05/11/20162:25PMBWBristol-Myers Squibb & AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multipl...
First and only immunostimulatory antibody approved in the European Union for multiple myeloma Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti in combination with Revlimid® (lenalidomide) and dexamethasone (Rd) ELOQUENT-2 demonstrated the Empliciti combination delivered... More...>>
05/11/201611:31AMBWEuropean Commission Approves the First & Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo® (nivolumab) + Ye...
Opdivo + Yervoy Regimen now approved for unresectable or metastatic melanoma patients, regardless of BRAF mutational status Approval of the Regimen marks a novel combination treatment for advanced melanoma patients, demonstrating the potential of targeting distinct and complementary immune pathways With this fifth EU approval... More...>>
05/05/20167:30AMBWModern Family Star Eric Stonestreet & His Mom, a Two Time Cancer Survivor, Join Forces to Raise Awareness of Immuno-Oncology ...
Ready. Raise. Rise. creates a social movement to honor cancer patients and caregivers and helps provide charitable donations to advocacy organizations Bristol-Myers Squibb and Eric Stonestreet call on anyone touched by cancer to raise and share a virtual flag to support the cancer community The Ready. Raise. Rise. campaign... More...>>
04/28/20166:10PMDJNDrugmakers Place Big Bets on Cancer Medicines
Despite a growing outcry over the rising cost of cancer treatments, drugmakers are placing multibillion-dollar bets on new medicines they expect will command premium prices and generate big sales. France's Sanofi SA said Thursday it made an unsolicited, $9.3 billion offer to purchase San Francisco-based Medivation... More...>>
04/28/20167:28AMDJNBristol-Myers Revenue Rises 8.7%,
By Tess Stynes Bristol-Myers Squibb Co. said its first-quarter revenue rose a better-than-expected 8.7%, boosted by the continued expansion of the pharmaceutical company's Opdivo cancer immunotherapy and growth of other key drugs. The pharmaceutical company's adjusted per-share earnings, excluding certain one-time... More...>>
04/28/20166:59AMBWBristol-Myers Squibb Reports First Quarter Financial Results
Increases First Quarter Revenues 9% to $4.4 Billion Posts First Quarter GAAP EPS of $0.71 and Non-GAAP EPS of $0.74 Achieves Significant European Regulatory Milestones in Immuno-Oncology Opdivo Approved for Previously Treated Advanced Renal Cell Carcinoma Expanded Use of Opdivo to Include Previously Treated Metastatic... More...>>
04/27/201610:00AMBWBristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4, 2016, in Boston. Murdo Gordon, senior vice president, Head of Worldwide Markets, will answer questions about the company at 11:20 a.m. EDT. Investors and the general public are invited to... More...>>
04/25/20166:59AMBWBristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food & Drug Administration ...
Designation based on results of Phase 3 study, CheckMate -141, in which Opdivo met its primary endpoint of overall survival, versus three standard of care options in this patient population Designation signals the urgent need for new treatment approaches in recurrent or metastatic squamous cell carcinoma of the head and... More...>>
04/22/20166:44AMDJNChina Eases Path for Foreign Drugmakers' Hepatitis C Treatments
SHANGHAI-- China will grant four global drug companies priority-review status to launch groundbreaking new hepatitis C treatments in China, a rare move to open the lucrative market to foreign players. China's Food and Drug Administration expedites domestic drug applications to encourage innovation. But its lengthy... More...>>
04/19/20169:30AMBWFirst Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus In...
Opdivo is the first and only PD-1 inhibitor to demonstrate a statistically significant improvement in overall survival compared to three standard of care options in this setting, based on CheckMate -141 Data from CheckMate -141 showed survival benefit with Opdivo in this overall population, regardless of PD-L1 expression... More...>>
04/17/20168:50PMDJNBristol's Opdivo Shows Benefits in Cancer Immunotherapy Trial
More than one-third of advanced melanoma patients treated in a study of Bristol-Myers Squibb Co.'s Opdivo have survived at least five years, researchers said, providing fresh evidence of the durable benefit cancer immunotherapy agents have for some patients. The study followed 107 patients who were enrolled in an... More...>>
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V:us D:20160527 04:36:21